Home   About the Journal  Editorial Board Reviewers   Online Journal  Writing Norm  Advertisement  Contact Us
You are here:Home => Online Journal => 7期肝癌的诊断和治疗 => 述评 =>
Immunotherapy for hepatocellular carcinoma
文章发布日期:2018年06月07日  来源:  作者:任正刚  点击次数:694次  下载次数:123次
Adjust font size:Small regular big

【Abstract】:In the past 10 years, the progress in systemic therapy for hepatocellular carcinoma (HCC) is attributed to the application of molecular target therapy and the improvement in immunotherapy. The immunosuppressive microenvironment of HCC enables HCC cells to avoid attack by the immune system, which is also an important reason for the progression of HCC. Improving immune killing of HCC and correcting immunosuppressive conditions are important strategies for immunotherapy for HCC. Tumor vaccine therapy based on HCC specific antigen, genetically engineered T lymphocytes, and basic research and bench-to-bedside translation of immune checkpoint inhibitors have significantly improved the outcome of immunotherapy. Further studies should be performed for immunotherapy combined with other antitumor therapies such as local ablation, molecular targeted therapy, and tumor vaccine therapy.
【Key words】:carcinoma, hepatocellular; immunotherapy; editorial
【引证本文】:REN ZG. Immunotherapy for hepatocellular carcinoma[J]. J Clin Hepatol, 2018, 34(7): 1371-1373. (in Chinese)
任正刚. 肝细胞癌的免疫治疗[J]. 临床肝胆病杂志, 2018, 34(7): 1371-1373.

Mail address: Editorial Office of Journal of Clinical Hepatology, 519 Dongminzhu Street, Changchun, Jilin, China Postal code: 130061 Tel:+86-431-88782542/3542
Journal of Clinical Hepatology Copyright © 2009 - 2013 Lcgdbzz.org. All Rights Reserv 吉ICP备10000617号